Tap & Unlock Your Funds! up to ₹50 lakhs

Followers

0
0
7
7
.
1
1
3
3
9
9
,
4
4
-59.30 (-1.19%)

As on 20 Feb, 2026 | 15:59

Open Trading A/c
Day Range
4,913.10
5,003.90
LH
52 Week Range
3,701.00
5,993.00
LH
Volume
* i
Bid / Ask
10,109.00
4,931.70 / 1.00

Pfizer Announcements

Pfizer Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2026 ,inter alia, to consider and approve...

30 Jan, 2026 | 04:45pm • Source: BSE

Pfizer Limited has informed the Exchange about change in Management

20 Jan, 2026 | 10:36am • Source: NSE

Intimation regarding change in Senior Management

20 Jan, 2026 | 09:26am • Source: BSE

Pfizer Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

09 Jan, 2026 | 12:20pm • Source:

Please find enclosed herewith the certificate confirming compliance with Regulation 74(5) of the SEBI (DP) Regulations, 2018, for the quarter ended December, 31, 2025.

09 Jan, 2026 | 12:04pm • Source: BSE

This is to inform you that the trading window for trading in shares of the Company shall remain closed from Wednesday, December 31, 2025 (close...

29 Dec, 2025 | 04:05pm • Source: BSE

Intimation pursuant to Regulation 30 of SEBI LODR regarding receipt of an order levying penalty from GST Authorities.

28 Dec, 2025 | 12:37pm • Source: BSE

Intimation pursuant to Regulation 30 of SEBI LODR regarding receipt of an order levying penalty from GST Authorities.

24 Dec, 2025 | 06:25pm • Source: BSE

Intimation regarding change in Senior Management Personnel of the Company - Resignation of Ms. Aditi Mehta - Category Lead, Vaccines.

23 Dec, 2025 | 01:41pm • Source: BSE

Press Release in respect of an exclusive Supply & Marketing Arrangement with Cipla Limited for certain brands.

19 Dec, 2025 | 11:34am • Source: BSE

Exclusive Supply and Marketing Arrangement with Cipla Limited for Pfizer Limited''s Brands Corex Dx, Corex LS, Dolonex and Neksium.

19 Dec, 2025 | 11:31am • Source: BSE

Pursuant to Regulations 30 and 33 of the Listing Regulations, we submit herewith the Unaudited Financial Results of the Company for the quarter and half...

12 Nov, 2025 | 03:37pm • Source: BSE

Pfizer Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2025 ,inter alia, to consider and approve...

03 Nov, 2025 | 06:02pm • Source: BSE

Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2025.

08 Oct, 2025 | 05:44pm • Source: BSE

We would like to inform you that, for the purpose of declaration of unaudited financial results of the Company for the quarter and half year...

29 Sep, 2025 | 05:40pm • Source: BSE

Unaudited Financial Results for quarter ended June 30, 2025

13 Aug, 2025 | 05:04pm • Source: BSE

Unaudited Financial results for the quarter ended June 30, 2025

13 Aug, 2025 | 04:58pm • Source: BSE

Pfizer Launches 20-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV20) for Adults in India, offering broad protection against Pneumococcal Disease.

11 Aug, 2025 | 07:20pm • Source: BSE

Pursuant to Regulation 30 of SEBI (LODR) Regulations 2015, we hereby inform that Company has announced the launch of its next generation 20-valent Pneumococcal Polysaccharide...

11 Aug, 2025 | 07:06pm • Source: BSE

Pfizer Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2025 ,inter alia, to consider and approve...

07 Aug, 2025 | 06:00pm • Source: BSE